Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms

Clinical Cancer Research

Volumn 6, Issue 5, 2000, Pages 1936-1948

  Bruns, Christiane J ^a   Harbison, Matthew T ^a   Davis, Darren W ^a   Portera, Charles A ^a   Tsan, Rachel ^a   McConkey, David J ^a   Evans, Douglas B ^a   Abbruzzese, James L ^a   Hicklin, Daniel J ^b   Radinsky, Robert ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GEMCITABINE; INTERLEUKIN 8; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPHOSPHORYLATION; CANCER GROWTH; CANCER REGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSTASIS; HUMAN; HUMAN CELL; LIVER METASTASIS; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CARCINOMA; PRIORITY JOURNAL; TUMOR REGRESSION; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL DIVISION; DEOXYCYTIDINE; ENDOTHELIAL GROWTH FACTORS; EPIDERMAL GROWTH FACTOR; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INTERLEUKIN-8; LYMPHOKINES; MALE; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PANCREAS; PANCREATIC NEOPLASMS; PHOSPHORYLATION; PROLIFERATING CELL NUCLEAR ANTIGEN; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 18844473781     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Wanebo, H. J., and Vezeridis, M. P. Pancreatic carcinoma in perspective. A continuing challenge. Cancer (Phila.), 78: 580-591, 1996.
2. Bukowsk, R. M. Biologic therapy in patients receiving salvage treatment. Semin. Oncol., 21: 96-99, 1994.
3. Moore, M. Clinical experience with gemcitabine in pancreatic cancer. Oncology, 11: 1615-1622, 1997.
4. Rothenberg, M. L., Abbruzzese, J. L., Portenoy, R. K., Robertson, J. M., and Wanebo, H. J. A rationale for expanding the endpoints for clinical trials in advanced pancreatic cancer. Cancer (Phila.), 78: 627-632, 1996.
5. Brand, R. E., and Tempero, M. A. Pancreatic cancer. Curr. Opin. Oncol., 10: 362-366, 1998.
6. Burris, H. A., III, Moore, M. J., and Anderson, J. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 15: 2403-2413, 1997.
7. Ahlgren, J. D. Chemotherapy for pancreatic carcinoma. Cancer (Phila.), 78: 654-663, 1996.
8. Hertel, L. W., Boder, G. B., Kroin, J. S., Rinzel, S. M., Poore, G. A., Todd, G. C., and Grindey, G. B. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res., 50: 4417-4422, 1990.
9. Touroutoglou, N., Gravel, D., Raber, M. N., Plunkett, W., and Abbruzzese, J. L. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann. Oncol., 9: 1003-1008, 1998.
10. Ciardiello, F., Damiano, V., Bianco, R., Bianco, C., Fontanini, G., DeLaurentiis, M., DePlacido, S., Mendelsohn, J., Bianco, A. R., and Tortora, G. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase. Am. J. Cancer Inst., 88: 1770-1776, 1996.
11. Petit, A. M., Rak, V., Hung, W. C., Rockwell, P., Goldstein, N., Fendly, B., and Kerbel, R. S. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol., 151: 1523-1530, 1997.
12. Perrotte, P., Takashi, M., Keiji, I., Hiroki, K., Beryl, Y. E., Hicklin, D. J., Radinsky, R., and Dinney, C. P. N. Anti-epidermal growth factor receptor antibody c225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin. Cancer Res., 5: 257-264, 1999.
13. Korc, M., Chandrasekar, B., Yamanaka, Y., Friess, H., Buchier, M., and Beger, H. G. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor α. J. Clin. Investig., 90: 1352-1360, 1992.
14. Funatomi, H., Itakura, J., Ishiwata, T., Pastan, I., Thompson, S. A., Johnson, G. R., and Korc, M. Amphiregulin antisense oligonucleotide inhibits the growth of T3M4 human pancreatic cancer cells and sensitizes the cells to EGF receptor-targeted therapy. Int. J. Cancer, 72: 512-517, 1997.
15. Elsasser, H-P., Adler, G., and Kern, H. F. Replication and regeneration of the pancreas. In: V. Liang and W. Go (eds.), The Pancreas: Biology, Pathobiology, and Disease, pp. 77-86. New York: Raven Press, Ltd., 1993.
16. Poston, G. J., Gillespie, J., and Guillou, P. J. Biology of pancreatic cancer. Gut, 32: 800-812, 1991.
17. Smith, J. J., Derynck, R., and Korc, M. Production of transforming growth factor α in human pancreatic cancer cells: evidence for a superagonist autocrine cycle. Proc. Natl. Acad. Sci. USA. 84: 7567-7570, 1987.
18. Yamanaka, Y., Friess, H., Kobrin, M. S., Buchler, M., Berger, H. G., and Korc, M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res., 13: 565-570, 1993.
19. Oikawa, T., Hitomi, J., Kono, A., Kaneko, E., and Yamaguchi, K. Frequent expression of genes for receptor tyrosine kinases and their ligands in human pancreatic cancer cells. Int. J. Pancreatol., 18: 15-23, 1995.
20. Chen, J., and Liu, T. H. Expression of EGF, TGF-α, EGFR, and c-erbB2 genes and their gene products in human pancreatic carcinoma cell lines. Centrablatt fur Pathologie, 140: 265-270, 1994.
21. Lemoine, N. R., Hughes, C. M., Barton, C. M., Poulsom, R., Jeffery, R. E., Kloppel, G., Hall, P. A., and Gullick, W. J. The epidermal growth factor receptor in human pancreatic cancer. J. Pathol., 166; 7-12, 1992.
22. Bouck, N., Stellmach, V., and Hsu, S. C. How tumors become angiogenic. Adv. Cancer Res., 69: 135-174, 1996.
23. Folkman, J., and D'Amore, P. A. Blood vessel formation: what is its molecular basis? Cell, 87: 1153-1155, 1996.
24. Pluda, J. M. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin. Oncol., 24: 203-218, 1997.
25. Kornmann, M., Beger, H. G., and Korc, M. Role of fibroblast growth factors and their receptors in pancreatic cancer and chronic pancreatitis. Pancreas, 17: 169-175, 1998.
26. Bruns, C. J., Harbison, M. T., Kuniyasu, H., Eue, I., and Fidler, I. J. In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia, 1: 50-62, 1999.
27. Kuniyasu, H., Ellis, L. M., Evans, D. B., Abbruzzese, J. L., Fenoglio, C. J., Bucana, C. D., Cleary, K. R., Tahara, E., and Fidler, I. J. Relative expression of E-cadherin and type IV collagenase genes predicts disease outcome in patients with resectable pancreatic carcinoma. Clin. Cancer Res., 5: 25-33, 1999.
28. Ferrara, N., Houck, K., Jakeman, L., and Leung, D. W. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr. Rev., 13: 18-32, 1992.
29. Azuma, M., Tamatani, T., Fukui, K., Yuki, T., Yoshida, H., Bando, T., Hoque, M. O., Kamogashira, T., Ogino, K., and Nishino, N. Identification of EGF as an angiogenic factor present in conditioned medium from human salivary gland adenocarcinoma cell clones with varying degrees of metastatic potential. Cancer Lett., 84: 189-198, 1994.
30. Schreiber, A. B., Winkler, M. E., and Derynck, R. Transforming growth factor-α: a more potent angiogenic mediator than epidermal growth factor. Science (Washington DC), 252: 1250-1253, 1986.
31. Goldman, C. K., Kim, J., Wong, W. L., King, V., Brock, T., and Gillespie, G. Y. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol. Biol. Cell, 4: 121-133, 1993.
32. Dinney, C. P. N., Parker, C., Dong, A., Fan, D., Eve, B. Y., Bucana, C., and Radinsky, R. Therapy of human transitional cell carcinoma of the bladder by oral administration of epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide. Clin. Cancer Res., 3: 161-168, 1997.
33. Fan, D., Poste, G., Ruffolo, R. R., Jr., Dong, Z., Seid, C., Earnest, L. E., Campbell, T. E., Clyne, R. K., Beltran, P. J., and Fidler, I. J. Circumvention of multidrug resistance in murine fibrosarcoma and colon carcinoma cells by treatment with the α-adrenoceptor antagonist furobenzazepine. Int. J. Oncol., 4: 789-798, 1994.
34. Radinsky, R., Risin, S., Fan, D., Dong, Z., Bielenberg, D., Bucana, C. D., and Fidler, I. J. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin. Cancer Res., 1: 19-31, 1995.
35. Parker, C., Roseman, B. J., Bucana, C. D., Tsan, R., and Radinsky, R. Preferential activation of the epidermal growth factor receptor in human colon carcinoma liver metastases in nude mice. J. Histochem. Cytochem., 46: 595-602, 1998.
36. Shi, S. R., Key, M. E., and Kalra, K. L. Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J. Histochem. Cytochem., 6: 741-748, 1991.
37. Weidner, N., Semple, J. P., Welch, W. R., and Folkman, J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med., 324: 1-8, 1991.
38. Sorkin, A., Helin, K., Waters, C. M., Carpenter, G., and Beguinot, L. Multiple autophosphorylation sites of the epidermal growth factor receptor are essential for receptor kinase activity and internalization: contrasting significance of tyrosine 992 in the native and truncated receptors. J. Biol. Chem., 267: 8672-8678, 1992.
39. Duello, T. M., Bertics, P. J., Fulgham, D. L., and Van Ess, P. J. Localization of epidermal growth factor receptors in first- and third-trimester human placentas. J. Histochem. Cytochem., 42: 907-915, 1994.
40. Campos-Gonzalez, R., and Glenney, J. R. Immunodetection of the ligand-activated receptor for epidermal growth factor. Growth Factors, 4: 305-331, 1991.
41. Wagner, M., Cao, T., Lopes, M. E., Hope, C., Van Nostrand, K., Kobrin, M. S., Fan, H. U., Buchler, M. W., and Korc, M. Expression of a truncated EGF receptor is associated with inhibition of pancreatic cancer cell growth and enhanced sensitivity to cisplatinum. Int. J. Cancer, 68: 782-792, 1996.
42. Liu, T., Chen, J., and Zeng, C. Effects of antisense epidermal growth factor and its receptor retroviral expression vectors on cell growth of human pancreatic carcinoma cell line. Chin. Med. J. (Engl. Ed.), 108: 653-659, 1995.
43. Schmiegel, W., Schmielau, J., and Hennebruns, D. Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer. Proc. Natl. Acad. Sci. USA, 94: 12622-12626, 1997.
44. Cip1 in growth inhibition mediated by blockade or overstimulation of epidermal growth factor receptors. Clin. Cancer Res., 3: 1943-1948, 1997.
45. Mendelsohn, J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin. Cancer Res., 3: 2703-2707, 1997.
46. Huang, S-M., Bock, J. M., and Harari, P. M. Epidermal growth factor receptor blockade with c225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res., 59: 1935-1940, 1999.
47. Baselga, J., Norton, L., Masui, H., Pandiella, Coplan, K., Miller, W. H., Jr., and Mendelsohn, J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst., 85: 1327-1333, 1993.
48. van Gog, F. B., Brakenhoff, R. H., Stigter-van Walsum, M., Snow, G. B., and van Dongen, G. A. Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer. Int. J. Cancer, 77: 13-18, 1998.
49. Aboud-Pirak, E., Hurwitz, E., Pirak, M. E., Bellot, F., Schlessinger, J., and Sela, M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma cell in vitro and in nude mice. J. Natl. Cancer Inst., 80: 1605-1611, 1988.
50. Pietras, R. J., Fendly, B. M., Chazin, V. R., Pegram, M. D., Howell, S. B., and Slamon, D. J. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene, 9: 1829-1838, 1994.
51. Bandyopadhyay, D., Mandai, M., Adam, L., Mendelsohn, J., and Kumar, R. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J. Biol. Chem., 273: 1568-1573, 1998.
52. Meyers, M. B., Merluzzi, V. J., Spengler, B. A., and Biedler, J. L. Epidermal growth factor receptor is increased in multidrug-resistant Chinese hamster and mouse tumor cells. Proc. Natl. Acad. Sci. (Wash.), 83: 5521-5525, 1986.
53. Nagane, M., Levitzki, A., Gazit, A., Cavenee, W. K., and Huang, H. J. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc. Natl. Acad. Sci. USA, 95: 5724-5729, 1998.
54. Benjamin, L. E., and Keshet, E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Natl. Acad. Sci. USA, 94: 8761-8766, 1997.
55. Koch, A. E., Polverini, P. J., Kunkel, S. L., Harlow, L. A., DiPietro, L. A., Elner, V. M., and Stricter, R. M. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science (Washington DC), 258: 1798-1801, 1992.
56. Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., and Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Investig., 103: 159-165, 1999.
57. Kong, H-L., and Crystal, R. G. Gene therapy strategies for tumor antiangiogenesis. J. Natl. Cancer Inst., 90: 273-286, 1998.
58. Kerbel, R. S., Viloria-Petit, A., Okada, F., and Rak, J. Establishing a link between oncogenes and tumor angiogenesis. Mol. Med., 4: 286-295, 1998.
59. Grugel, S., Finkenzeller, G., Weindel, K., Barleon, B., and Marme, D. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J. Biol. Chem., 270: 25915-25919, 1995.
60. Rozakis-Adcock, M., Fernley, R., Wade, J., Pawson, T., and Bowtell, D. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the Ras activator mSosl. Nature (Lond.), 363: 83-85, 1993.
61. Rak, J., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., and Kerbel, R. S. Mutant ras oncogene up-regulates VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res., 55: 4575-4580, 1995.
62. Strieter, R. M., Kunkel, S. L., Einer, V. M., Martonyi, C. L., Koch, E. A., and Polverini, P. J. Interleukin-8. A corneal factor that induces neovascularization. Am. J. Pathol., 141: 1279-1284, 1992.